Innovation in Recombinant Enzymes and Reduced Pill Burden

Blackstone Life Sciences has invested $250 million in Anagram Therapeutics, accelerating the development of ANG003, a treatment for Exocrine Pancreatic Insufficiency (EPI). ANG003 is an innovative, non-animal-derived recombinant enzyme replacement therapy candidate designed to address the significant pill burden experienced by patients with Cystic Fibrosis (CF). Currently, patients often have to take up to 40 pills daily. ANG003 is designed to provide the same therapeutic effect with only one pill per meal, totaling three pills per day. This is expected to dramatically improve patient compliance, ultimately increasing treatment success rates and significantly improving patients' quality of life.

Overcoming the Limitations of Porcine-Derived Treatments and Establishing a Stable Supply Chain

The current standard of care for EPI, pancreatic enzyme replacement therapy (PERT), is derived from porcine pancreas glands. This reliance on porcine sources has led to chronic supply shortages due to unforeseen events such as swine disease outbreaks and reduced slaughter rates, causing significant anxiety for patients. In contrast, ANG003, developed by Anagram Therapeutics, is a mixture of microbial-derived recombinant lipase, protease, and amylase, completely eliminating animal-derived components. This approach eliminates supply chain risks, ensures consistent product quality, and reduces costs, potentially setting a new standard in the digestive enzyme pharmaceutical market.

Phase 2 Clinical Trial and Global Market Competition

Anagram Therapeutics has successfully completed the preclinical and early clinical stages of ANG003, supported by over $30 million in initial funding from the Cystic Fibrosis Foundation (CFF), and is now entering a global Phase 2 clinical trial. This Phase 2 trial aims to validate the safety of ANG003 in patients with cystic fibrosis and to demonstrate its superiority to AbbVie's blockbuster PERT treatment, Creon, which generates over $1.1 billion in annual revenue. If the clinical trial demonstrates superior convenience and non-inferior efficacy compared to Creon, Anagram Therapeutics has the potential to become a major player in the $3 billion global market for EPI treatments.

Blackstone's Focus on Late-Stage Clinical Asset Investments

This investment aligns with Blackstone's strategy of making significant capital investments in late-stage clinical assets in the biotechnology sector. Blackstone Life Sciences successfully closed its sixth life sciences fund with $6.3 billion in capital on March 2026, providing substantial resources to support the commercialization of innovative drugs from private venture companies. Blackstone aims to lead the entire process, from clinical development and regulatory approval to commercial launch, to increase the success rate of high-risk pipelines. Similar to the successful establishment and subsequent sale of Anthos Therapeutics to Novartis for $925 million, this investment in Anagram Therapeutics reflects Blackstone's sophisticated healthcare investment strategy, focused on strengthening platform capabilities and generating high returns.